The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19.
Pereira, Marcos;
Paixão, Enny;
Trajman, Anete;
de Souza, Ramon Andrade;
da Natividade, Marcio Santos;
Pescarini, Julia M;
Pereira, Susan Martins;
Barreto, Florisneide Rodrigues;
Ximenes, Ricardo;
Dalcomo, Margareth;
+4 more...Ichihara, Maria Yury;
Nunes, Ceuci;
Barral-Netto, Manoel;
Barreto, Maurício L;
(2020)
The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19.
RESPIRATORY RESEARCH, 21 (1).
178-.
ISSN 1465-9921
DOI: https://doi.org/10.1186/s12931-020-01439-4
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.
